GANX Company Profile and Key Details

Q: Who are the executives of GANX?

Dr. Natalia Perez-Carmona Ph.D.Head of BiologyDr. Joanne Taylor Ph.D.Senior Vice President of Research & Scientific AdvisorDr. Terenzio Ignoni Pharm.D.Senior Vice President of Technical OperationsDr. Xavier Barril Ph.D.Chief Technology OfficerDr. Manolo Bellotto Ph.D.GM & Chief Strategy OfficerDr. Ana Maria Garcia-Collazo Ph.D.Head of ResearchDr. Khalid Islam Ph.D.Founder & ChairmanMr. Salvatore CalabreseChief Financial Officer & Corporation Sec.Mr. Gianluca FuggettaPrincipal Accounting Officer & Senior Director of Corporation ReportingMr. Matthias Alder LIC. IUR., LL.M.Pres, Chief Executive Officer & DirectorMr. C. Evan BallantyneChief Financial Officer & Sec.

NASDAQ : GANX

Gain Therapeutics

$1.79

-0.02-1.10%

At Close 4:00 PM

61.1

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Gain Therapeutics, Inc. (GANX) stock declined over -1.10%, trading at $1.79 on NASDAQ, down from the previous close of $1.81. The stock opened at $1.78, fluctuating between $1.78 and $1.85 in the recent session.

Stock Snapshot

1.81

Prev. Close

76.35M

Market Cap

1.78

Day Low

-3.09

P/E Ratio

-0.58

EPS (TTM)

-1.17

Cash Flow per Share

1.78

Open

42.65M

Number of Shares

1.85

Day High

96.28%

Free Float in %

0.78

Book Value

585.74K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 08, 2026	1.78	1.86	1.78	1.79	590.68K
Jul 07, 2026	1.81	1.84	1.72	1.81	741.63K
Jul 06, 2026	1.91	1.94	1.80	1.81	564.99K
Jul 02, 2026	1.97	2.03	1.89	1.91	766.61K
Jul 01, 2026	2.00	2.15	1.92	1.99	1.52M
Jun 30, 2026	1.95	2.24	1.93	2.03	3.76M
Jun 29, 2026	1.75	1.99	1.75	1.98	11.48M
Jun 26, 2026	1.72	1.77	1.68	1.75	522.39K
Jun 25, 2026	1.71	1.75	1.71	1.72	283.87K
Jun 24, 2026	1.81	1.87	1.74	1.74	272.16K
Jun 23, 2026	1.83	1.90	1.77	1.77	378.82K
Jun 22, 2026	1.88	1.95	1.84	1.85	790.95K
Jun 18, 2026	1.81	1.90	1.80	1.88	498.43K
Jun 17, 2026	1.79	1.88	1.77	1.78	381.72K
Jun 16, 2026	1.78	1.86	1.77	1.79	599.97K
Jun 15, 2026	1.71	1.79	1.70	1.75	449.48K
Jun 12, 2026	1.65	1.71	1.64	1.68	482.86K
Jun 11, 2026	1.64	1.70	1.60	1.69	530.96K
Jun 10, 2026	1.62	1.75	1.62	1.64	362.27K
Jun 09, 2026	1.67	1.70	1.56	1.65	1.3M

Contact Details

Bethesda, MD 20814

United States

https://www.gaintherapeutics.com 301 500 1556

About Company

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.

Stock Peers

ARGX

-4.64-0.50%

argenx SE$915.30 REGN

-13.35-1.97%

Regeneron Pharmaceuticals, Inc.$662.88 MDGL

20.04+3.67%

Madrigal Pharmaceuticals, Inc.$565.40 UTHR

-9.36-1.66%

United Therapeutics Corporation$554.34 VRTX

-23.82-4.56%

Vertex Pharmaceuticals Incorporated$498.43 KRYS

6.8+1.84%

Krystal Biotech, Inc.$375.40 PRAX

9.04+2.79%

Praxis Precision Medicines, Inc.$332.99 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.91+0.59%

Alnylam Pharmaceuticals, Inc.$323.50 LGND

-4.55-1.42%

Ligand Pharmaceuticals Incorporated$314.88

Company Overview

Gain Therapeutics, Inc. (NASDAQ:GANX) closed at $1.79 USD, losing -$0.02 (-1.10%) from the previous close of $1.81. The stock is currently mid-range between its 52-week high and low $1.41 and $4.34. With a market capitalization of about $76.35 million, Gain Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.16). Key stats such as the average daily volume over the past year has been around 849.66 thousand shares, volume is running light vs its 52-week average. Headquartered in Bethesda, MD, Gain Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gene Mack, the company employs approximately 23 people and listed since March 19, 2021. Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 28.53%, SMA50 5.24%, SMA200 17.95%). The stock’s 14-day RSI is 61.29 (firm momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -42.86% below its high and over 75.89% above its low. Average 10-day trading volume of 2.78 million shares is significantly above the 3-month average of 837.40 thousand, indicating heightened recent market interest.

Valuation Metrics

Gain Therapeutics, Inc. trades at a P/E ratio of -3.14, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.49 trading at moderately above to book value. The P/FCF stands at -4.01, also above market averages.

Dividend & Fair Value

Gain Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.61. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Gain Therapeutics, Inc. generated EPS of -$0.64 over the past year. Five-year average earnings growth is -37.02%. Wall Street analysts project EPS growth of 2.3% annually over the next five years. The latest quarter delivered EPS of -$0.13. The next quarter is forecast at -$0.14. Next year's EPS is expected at $23.12. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $5.00. The high target offers 402.79% upside. The low target suggests 179.33% downside. The mean target is $7.50. This offers 318.99% upside. Gain Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 0.0%. The prior quarter beat by -21.43%. Over the last six quarters, Apple has recorded several small beats. These include -38.89% in March 27, 2025.

Shareholding & Insider Activity

Gain Therapeutics, Inc. has 35.95 million shares outstanding. The public float is 29.58 million shares, elevated short interest at 0.73% of float. This equals 243.00 thousand shares. The short ratio is 0.82 days. Institutional investors hold 10.96% of the float. Insiders own 3.64%. RICHMAN ERIC I holds 277.63 thousand shares, Islam Khalid has 50.00 thousand shares and Riley Jeffrey Scott has 30.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Gain Therapeutics generated $55.18K in revenue, or $0.00 per share. Gross margin was -45.67%, operating margin -40328.25%, and net profit margin -40354.33%. Returns are negative, with ROA at -119.66% and ROE at -177.03%.
On valuation metrics, Gain Therapeutics trades at a P/E of -3.14, P/S of 0.00 and P/B of 5.49. The current ratio is 4.69 and quick ratio is 4.69. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -28.81.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Gain Therapeutics posted revenue of $55.18K, down slightly from $140.11K in the prior quarter. Gross profit was - $25.20K (margin -45.67%). Operating income was - $22.25M (margin -40328.3%). Net income was- $22.27M (EPS - $1.71).
The company ended the quarter with $16.79M in cash and short-term investments, a total debt of $1.03M, and net debt of - $10.77M. Total assets were $18.61M, with equity of $12.58M. Financials further reflected weakness, with operating cash flow of - $18.87M, free cash flow of - $18.88M, and capital expenditures of - $15.36K.

Price Forecast & Outlook

Our AI price prediction model suggests that Gain Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.79%, with price expected at $1.84 by July 22, 2026, within a range of $1.69 to $1.96 3-Month Outlook: Projected fall of -70.39%, reaching $0.53 by October 06, 2026, with a range of $0.35 to $0.63. 1-Year Outlook: Projected gain of 389.94%, with price at $8.77 by July 08, 2027, within a range of $0.04 to $15.09.

Key Takeaways

Gain Therapeutics, Inc. (NASDAQ:GANX) shares are down -38.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Gain Therapeutics, Inc. trading at a premium to the broader market with a P/E of -3.14. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $8.67, suggesting 384.36% upside. Our AI forecast model points to short-term strength (2.79% over two weeks), a medium-term fall (-70.39% over three months), and a longer-term gain (389.94% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Gain Therapeutics, Inc. (GANX) stock price?

Gain Therapeutics, Inc. (NASDAQ: GANX) stock price is $1.79 in the last trading session. During the trading session, GANX stock reached the peak price of $1.85 while $1.78 was the lowest point it dropped to. The percentage change in GANX stock occurred in the recent session was -1.1% while the dollar amount for the price change in GANX stock was - $0.02.

GANX's industry and sector of operation?

The NASDAQ listed GANX is part of Biotechnology industry that operates in the broader Healthcare sector. Gain Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GANX?

Dr. Natalia Perez-Carmona Ph.D.
Head of Biology
Dr. Joanne Taylor Ph.D.
Senior Vice President of Research & Scientific Advisor
Dr. Terenzio Ignoni Pharm.D.
Senior Vice President of Technical Operations
Dr. Xavier Barril Ph.D.
Chief Technology Officer
Dr. Manolo Bellotto Ph.D.
GM & Chief Strategy Officer
Dr. Ana Maria Garcia-Collazo Ph.D.
Head of Research
Dr. Khalid Islam Ph.D.
Founder & Chairman
Mr. Salvatore Calabrese
Chief Financial Officer & Corporation Sec.
Mr. Gianluca Fuggetta
Principal Accounting Officer & Senior Director of Corporation Reporting
Mr. Matthias Alder LIC. IUR., LL.M.
Pres, Chief Executive Officer & Director
Mr. C. Evan Ballantyne
Chief Financial Officer & Sec.

How GANX did perform over past 52-week?

GANX's closing price is 26.95% higher than its 52-week low of $1.41 where as its distance from 52-week high of $4.34 is -58.76%.

How many employees does GANX have?

Number of GANX employees currently stands at 23.

Link for GANX official website?

Official Website of GANX is: https://www.gaintherapeutics.com

How do I contact GANX?

GANX could be contacted at phone 301 500 1556 and can also be accessed through its website. GANX operates from 4800 Montgomery Lane, Bethesda, MD 20814, United States.

How many shares of GANX are traded daily?

GANX stock volume for the day was 585.74K shares. The average number of GANX shares traded daily for last 3 months was 849.66K.

What is the market cap of GANX currently?

The market value of GANX currently stands at $76.35M with its latest stock price at $1.79 and 42.65M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	23
Beta	0.16
Sales or Revenue	$55.18K
5Y Sales Change%	0.206%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

GANX Company Profile and Key Details

Gain Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways